Ultrapotent compound may help treat
, reduce recurrence
from Purdue University via EurekAlert!
, is the leading cause of healthcare-associated infection in the U.S. Only two antibiotics, vancomycin and fidaxomicin, are FDA approved for the treatment of
, but even these therapies suffer from high treatment failure and recurrence. Now, Purdue University innovators have advanced novel compounds they developed to help treat patients with
, one of only four bacteria considered an urgent threat by the Centers for Disease Control and Prevention. Their work is published in the
Journal of Medicinal Chemistry.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063